This Article Full Text Full Text (PDF) Data Supplement Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haller, D. G. Articles by Cox, J. V. Search for Related Content PubMed Articles by Haller, D. G. Articles by Cox, J. V. Social Bookmarking                            What's this?

Provisional Clinical Opinion

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

On January 13, 2009, ASCO released its first provisional clinical opinion (PCO). The subject of the PCO is KRAS testing in patients with metastatic colon cancer who are eligible for anti-EGFR antibody therapy. The PCO was prompted by cumulative data from many retrospective studies showing that patients with metastatic colon cancer with tumoral mutations in KRAS do not respond to these agents. The purpose of PCOs is to provide ASCO members direction on issues that have been informed by recent data that should affect clinical practice, such as KRAS testing. The need for timely opinion from ASCO is apparent as . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. V. Cox Medicare's Seasons J. Oncol. Pract, March 1, 2009; 5(2): 49 - 49. [Full Text] [PDF]